Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South America. Approximately 153 subjects will be enrolled in a randomization (ratio 2:1).
Epistemonikos ID: 807a968b2077f1bda50dad4e6a7b39acef2399c6
First added on: May 04, 2024